Trovagene said this week that Rodney Markin has joined the company's board of directors.
Markin, a hepatic pathologist by training, is a leading authority in the field of laboratory automation, Trovagene said. He is currently chief technology officer, associate vice chancellor for business development, and professor of pathology and microbiology at the University of Nebraska Medical Center.
Markin founded and served as CEO of LAB-InterLink, a spinout of UNMC that provided products for hospital-based laboratory automation systems before it was sold to Cardinal Health. Markin is also currently the chairman of Transgenomic, a director of the Children's Hospital and Medical Center Foundation, and a member of the board of trustees of the Keck Graduate Institute.
Trovagene also said this week that Chris McGuigan has resigned from the company's board to focus on other opportunities.
Empirical Bioscience said this week that it has elected Richard Leach to its board of directors.
Leach's experience in genome sequencing and its application in fields such as personalized medicine will help Empirical grow its existing and prospective markets for PCR reagents used in human, animal, and plant DNA, the company said.
Leach is currently vice president of business development at Complete Genomics, where he has worked for the past three years. Before that he was vice president at DeCode Genetics. He has also served as a scientific and business consultant at the Shady Grove Center for Preimplantation Genetics in Rockville, Md.; founder and chief science officer at Teneo Sciences; senior field applications scientist at Affymetrix; scientist in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research; and visiting scientist at the National Cancer Institute.